Johnson & Johnson (JNJ) closed at $272.70 on November 18, 2026, down 2.2% from the previous close, on volume of 5,497,368 shares (30-day average 7,662,263).
Data as of November 18, 2026.
18-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 23, 2026 | Put Spread | 30-Oct-26255 : 260 P | 21,820 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 17, 2026. See the largest for 5, 30, 60 and 90 days
Fate of Trump's new FDA commissioner nominee will fall on Senate Democrats
Seeking Alpha News (Wed, 18-Nov 10:22 AM ET)
Trump abandons Heidi Overton as FDA commissioner nominee: reports
Seeking Alpha News (Tue, 17-Nov 10:17 PM ET)
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Tue, 17-Nov 8:50 AM ET)
White House getting antsy over FDA commissioner nominee Heidi Overton
Seeking Alpha News (Mon, 16-Nov 5:32 PM ET)
Business Wire (Mon, 16-Nov 8:00 AM ET)
M&A News: Johnson & Johnson Has $3.4B Eye Biotech Ollin Biosciences in Its Sights
TipRanks (Mon, 16-Nov 6:54 AM ET)
J&J in discussions to buy Ollin Biosciences for up to $3.4B - report
Seeking Alpha News (Mon, 16-Nov 12:21 AM ET)
Globe Newswire (Tue, 10-Nov 6:35 PM ET)
PRNewswire (Tue, 10-Nov 8:01 AM ET)
PRNewswire (Sun, 8-Nov 11:01 AM ET)
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Johnson & Johnson trades on the NYSE stock market under the symbol JNJ.
As of November 18, 2026, JNJ stock price declined to $272.70 with 5,497,368 million shares trading.
JNJ has a beta of -0.40, meaning it tends to be less sensitive to market movements. JNJ has a correlation of 0.04 to the broad based SPY ETF.
JNJ has a market cap of $656.67 billion. This is considered a Mega Cap stock.
Last quarter Johnson & Johnson reported $25 billion in Revenue and $2.59 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.06.
In the last 3 years, JNJ traded as high as $290.25 and as low as $140.68.
The top ETF exchange traded funds that JNJ belongs to (by Net Assets): VTI, VOO, IVV, SPY, VTV.
JNJ has outperformed the market in the last year with a price return of +39.3% while the SPY ETF gained +10.8%. JNJ has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +4.4% and +2.5%, respectively, while the SPY returned -5.3% and -3.2%, respectively.
JNJ support price is $273.47 and resistance is $283.93 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that JNJ shares will trade within this expected range on the day.